MRFRの分析によると、世界の腫瘍アブレーション市場は予測期間中、11.81％の注目すべきCAGRを達成し、2030年末までに24億5,974万ドルを超えると推定されます。主要な市場参加者は、腫瘍アブレーションの方法を改善および推進するための研究開発に積極的に取り組んでいます。さらに、同様に、高周波除去法に関連するいくつかの危険性があります。たとえば、知覚過敏、注入部位の浅い皮膚汚染、目的の神経に隣接する構造への熱害、皮膚を麻痺させるために使用される鎮静剤に対する過敏感反応などです。それは氷山の一角に過ぎません。
疾患の蔓延は、優れた治療法への関心を拡大しています。過度の喫煙と飲酒は、世界的な悪性腫瘍の増加に答えられる重要な変数です。世界中で疾患の共通性が拡大していることが、2021年から2030年までの世界的な腫瘍アブレーション市場における重要な推進要因となっています。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1.1 MARKET SYNOPSIS
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 LIST OF ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.4 FORECASTING TECHNIQUES
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.5.1 BOTTOM-UP APPROACH
3.5.2 TOP-DOWN APPROACH
3.6 DATA TRIANGULATION
3.7 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF CANCER ACROSS THE GLOBE
4.2.2 RISING DEMAND FOR MINIMALLY INVASIVE TUMOR ABLATION TECHNIQUES
4.2.3 GROWING NUMBER OF PUBLIC-PRIVATE INITIATIVES AND FUNDING TO SUPPORT ONGOING RESEARCH ACTIVITIES RELATED TO TUMOR ABLATION
4.3 RESTRAINTS
4.3.1 SIDE-EFFECTS AND COMPLICATIONS ASSOCIATED WITH TUMOR ABLATION
4.3.2 DELAY IN APPROVAL AND UNFAVORABLE REGULATORY POLICY AND REIMBURSEMENT SCENARIO
4.4 OPPORTUNITY
4.4.1 RISING R&D ACTIVITIES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES ANALYSIS
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 BARGAINING POWER OF BUYERS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 COVID-19 IMPACT ANALYSIS
5.3.1 IMPACT ON AVAILABILITY OF SURGICAL FACILITIES
5.3.2 IMPACT ON KEY PLAYERS
5.3.3 IMPACT ON CLINICAL TRIALS
5.3.4 IMPACT ON SUPPLY CHAIN
6 GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY
6.1 OVERVIEW
6.2 RADIOFREQUENCY
6.3 MICROWAVE
6.4 IRREVERSIBLE ELECTROPORATION
6.5 CRYOABLATION
6.6 OTHERS
7 GLOBAL TUMOR ABLATION MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 SURGICAL ABLATION
7.3 PERCUTANEOUS ABLATION
7.4 LAPAROSCOPIC ABLATION
8 GLOBAL TUMOR ABLATION MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 LUNG CANCER
8.3 KIDNEY CANCER
8.4 LIVER CANCER
8.5 OTHERS
9 GLOBAL TUMOR ABLATION MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITAL AND CLINICS
9.3 SPECIALITY CENTERS
9.4 OTHERS
10 GLOBAL TUMOR ABLATION MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 JAPAN
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL TUMOR ABLATION MARKET
11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL TUMOR ABLATION MARKET
11.5 KEY DEVELOPMENT ANALYSIS
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
11.6.2 MERGER &ACQUISITION
11.7 FINANCIAL MATRIX
11.7.1 SALES (USD MILLION), 2020
11.7.2 R&D EXPENDITURE (USD MILLION), 2020
12 DRG COST OF CURATIVE TREATMENT
12.1 DIAGNOSIS-RELATED GROUP (DRG)
12.2 BIOPSY PROCEDURE REIMBURSEMENT
12.3 ABLATION PROCEDURE REIMBURSMENT
12.3.1 LIVER ABLATION PROCEDURE REIMBURSMENT
12.3.2 KIDNEY ABLATION PROCEDURE REIMBURSMENT
12.3.3 LUNG ABLATION PROCEDURE REIMBURSMENT
12.4 IMAGING PROCEDURE REIMBURSMENT
12.5 TOTAL CURATIVE TREATMENT COSTS
13 COMPANY PROFILES
13.1 SONACARE MEDICAL
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCTS/SERVICES OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 MEDTRONIC PLC
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS/SERVICES OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 EDAP TMS
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 PRODUCTS/SERVICES OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 SWOT ANALYSIS
13.3.6 KEY STRATEGIES
13.4 ANGIODYNAMICS
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL OVERVIEW
13.4.3 PRODUCTS/SERVICES OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 SWOT ANALYSIS
13.4.6 KEY STRATEGIES
13.5 HEALTHTRONICS, INC.
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 PRODUCTS/SERVICES OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 SWOT ANALYSIS
13.5.6 KEY STRATEGIES
13.6 JOHNSON & JOHNSON
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS/SERVICES OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 BOSTON SCIENTIFIC CORPORATION
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 PRODUCTS/SERVICES OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 MISONIX, INC.
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL OVERVIEW
13.8.3 PRODUCTS/SERVICES OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 SWOT ANALYSIS
13.8.6 KEY STRATEGIES
13.9 HISTOSONICS, INC.
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 PRODUCTS/SERVICES OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 SWOT ANALYSIS
13.9.6 KEY STRATEGIES
13.10 BIOTRONIK
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 PRODUCTS/SERVICES OFFERED
13.10.4 KEY DEVELOPMENTS
13.10.5 SWOT ANALYSIS
13.10.6 KEY STRATEGIES
14 APPENDIX
14.1 REFERENCES
14.2 RELATED REPORTS
